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MICROCYSTINS AS AGENTS FOR
TREATMENT OF CANCER

SUMMARY OF THE INVENTION

CONTINUING APPLICATION DATA
5

This application claims benefit of U.S. Provisional Application No. 60/799,013, filed May 10, 2006, which is incorporated by reference herein in its entirety.
FIELD OF THE INVENTION
This invention relates to the use of microcystins as agents
for treatment of cancer. Also provided are methods of screening for microcystins with improved cytotoxicity.

10

15

BACKGROUND
Phosphorylation of intracellular proteins is a key mechanism in the regulation of signal transduction. Kinases,
enzymes that catalyze protein phosphorylation, are mediators
of the signal cascades, which activate multiple pathways
involving the governance of cell division and cell death. Phosphatases are enzymes that counter the activity ofkinases and
remove organic phosphates from their active sites on regulatory molecules, which generally cause cessation of the activation signals. The importance of protein phosphatases in cell
biology is underscored by the estimation that these proteins
constitute greater than 1% of all of the proteins encoded in the
human genome (1). Mammalian protein phosphatases have
been placed into five subfamilies, designated PP1, PP2A,
PP2B, PP5 and PP7 [reviewed in (2)].
Microcystins are inhibitors ofPP1 and PP2A and are generally known as hepatotoxins that result from cyanobacterial
contamination of water supplies. Structurally, microcystins
are cyclic heptapeptides with the basic structure cyclo (D-Ala
L-X-erythro-b-methyl-D-iso-ASP-L-Y-adda-D-iso-Glu-Nmethyldehydro-Ala) where L-X and L-Y represent variable
L-amina acids, and Adda is the b-amino acid 3-amino-9methoxy-2, 6, 8-trimethyl-1 0-pheny ldeca -4, 6-dienoic
acid
(3). The most commonly studied microcystin is microcystin
LR (FIG. 6), in which the two variable amino acids are leucine
and arginine. The structures of at least 50 microcystin variants
have been determined (4) differing almost exclusively in the
two variable residues, which can be other L-amina acids in
substitution for leucine and arginine. The variable nature of
these compounds suggests that they may have a spectrum of
biological effects and that there are opportunities for combinatorial engineering of therapeutic microcystin compounds.
The specific hepatic toxicity of microcystins results from
the restricted hepatic expression of the organic anion transporters OATP1B1, OATP1B3 andOATP1A2, which mediate
the cellular uptake of microcystins. OATP 1B 1 and OATP 1B3
transporters have previously been known as Liver Specific
Transporters 1 and 2 (LSTl and LST2), respectively, in recognition of gene expression limited to the liver. The potential
potency of microcystin toxins in cancer cells has been difficult to examine due to the absence of expression of these
transporters in most cancer cell lines. However, there is evidence for the expression of these transporters in tumors.
Western blot analyses have detected the expression of both
OATP1B1 and OATP1B3 in hepatocellular carcinoma (5, 6).
Also, Abe et a!. (7) have reported that OATP1B1 and
OATP1 B3 are expressed in a few cell lines created from liver,
colon, and pancreatic tumors, suggesting that there may be a
wider distribution of transporter gene expression in tumors
than in normal tissues.
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The present invention provides new methods for treating
cancers, including treating tumors and/or metastatic disease
and/or inhibiting the growth of tumors. The methods and
combination therapies are preferably directed towards the
treatment of OAT1B1- and/or OAT1B3-expressing cancers
such as lung cancers, breast cancer, colon cancer, hepatocellular carcinoma and other tumors.
Accordingly, one aspect of the invention provides a method
for treating cancer comprising administering to a subject in
need thereof a pharmaceutically effective amount of a microcystin. Non-limiting examples of cancers to be treated are
hepatocellular cancer, gastrointestinal cancer, lung cancer,
gastric cancer, colon cancer, pancreatic cancer, gall bladder
cancer, breast cancer, glioblastoma, and metastatic cancers
and intraperitoneal disseminations thereof. The cancer is
preferably hepatocellular cancer, gastrointestinal cancer, or
non-small cell lung cancer. The microcystin can be a heptapeptide with the basic structure cyclo (D-Ala-X-erythro-~
methyl-D-iso-Asp-Y-Adda-D-iso-Glu-N -methyldehydroAla ), where X andY represent variable amino acids, andAdda
is the ~-amino acid, 3-amino-9-methoxy-2,6,8-trimethyl-10phenyldeca-4,6-dienoic acid. Preferably, X andY are L amino
acids. More preferably, X is leucine andY is either arginine,
phenylalanine, or tryptophan.
Another aspect of the invention contemplates a combination therapy wherein a microcystin is used in combination
with other cancer treatment modalities as known in the art.
The present invention also provides a method of screening
for a microcystin with improved cytotoxicity, using cells
transfected with at least one of OATP1B1 and OATP1B3.
Preferably, the cells are transfected with OATP1B3.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1. Scatter plots displaying the expression levels of
OATP1B3 (A), THTR2 (B) and OATP1A2 (C) for each of the
19 individual lung tumors(.._) and normal tissue C•) pairs.
The solid line shows the median of the data set, whilst the
dotted lines display the expression level in a reference sample
from a normal tissue known to express the gene of interest.
The data presented are expression level of each individual
sample following normalization to ~-actin.
FIGS. 2A-2B. Expression levels of OATP1B1 and
OATP1B3 in normal liver, transfected HeLa cells, immortalized hepatocyte cell lines, hepatocellular carcinoma cells
(HCC), and lung cancer cell lines. Cells were collected and
DNase treated RNA isolated as described in the Materials and
Methods. Following eDNA synthesis, expression levels of
OATP1B1 (A) and OATP1B3 (B) were analyzed using quantitative real-time PCR; ~-actin levels were used to normalize
the expression. The data presented are the Mean±SD of duplicate analysis. Protein phosphatases PP1 and PP2A are ubiquitously expressed in all of the cell lines. Whole celllysates of
Lung cancer (C) Hepatocellular carcinoma (D) cell lines,
with HeLa cells used as a reference, were taken and equal
amounts (25 flg/lane) of total protein were separated on a 10%
SDS-PAGE gel, transferred to Nitrocellulose and immunoblotted for both PP1 and PP2A as described in the Materials
and Methods. ~-actin was used to demonstrate equal loading.
FIGS. 3A-3D. Uptake of radiolabeled OATP1B1 and
OATP1B3 substrates. Cells were seeded in 6 well plates,
transfected and assayed for uptake 48 hours later as described
in the Material and Methods. A. [3 H]-BQ123 (0.5 f.LM for 30
minutes), a substrate ofboth OATP 1B 1 and OATP 1B3 and B.
3
[ H]-CCK8 (5 nM for 10 minutes), a substrate specific for

US 9,006,173 B2
3
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OATP1B3, both substrates were also co-incubated in the
presence of the competitive substrate BSP (50 f.LM). The data
shown are the mean±SD of 3 replicate experiments. (C)
Growth inhibition of OATP1B1 (circles) and OATP1B3transfected HeLa cells (triangles), and mock-transfected
HeLa cells (squares) exposed to microcystin LR in the presence (open symbols) and absence (filled symbols) of the
uptake inhibitor BSP. The cells were seeded in 96 wells plates
24 hours following transfection with either the control plasmid piRESneo2, OATP1B1 or OATP1B3 containing vectors.
Twenty-four hours after seeding, the cells were exposed to a
range of microcystin LR concentrations for 72 hours with or
without the competitive transport substrate BSP (50 f.LM).
Growth inhibition was determined using the SRB dye assay
as described in the Materials and Methods and data are presented as the percent of untreated control growth. The data
shown are the mean±SD. of 3 replicate experiments. (D)
Clonogenic survival of HeLa cells transfected with
piRESneo2 C•), OATP1B1 (e)orOATP1B3 (T) following a
72 hour exposure to microcystin LR. The data shown are the
mean±SD. of3 replicate experiments. (E) Growth inhibition
ofOATP1B1-transfected HeLa cells exposed to microcystin
LR for 1 C•), 6 (.._)and 72 (T) hours. Growth inhibition was
determined using the SRB dye assay and data are presented as
the percent of untreated control growth. The data shown are
the mean±SD. of3 replicate experiments.
FIGS. 4A-4C. Correlations between growth inhibition and
in vitro enzyme inhibition (data from Table 2). The relationship between the growth inhibition IC 50 for the microcystin
analogs and the in vitro enzyme inhibition IC 50 ofPP2A (A),
and PP1 (B). The filled circles (e) represent the microcystin
analogs LW, LF, RR, and YR. The open square (D) is microcystin LR, and the closed square C•) is okadaic acid. The
Linear regression analysis was performed using the GRAPHPAD PRISM® Software. Inhibition of total phosphatase
activity in transfected HeLa cells exposed to equitoxic concentrations (IC 90 ) of the microcystin analogs (C). Intra-cellular phosphatase enzyme inhibition was determined using
whole cell lysates prepared from transfected HeLa cells
exposed to IC90 concentrations of the Microcystinanalogs for
6 hours as described in the Materials and Methods. 20 ng of
cellular protein was incubated in phosphatase assay buffer in
the presence of [33 P]-ATP labeled MyBP for 10 minutes, after
which the reaction was stopped with TCA and released [33 P]
was determined by liquid scintillation counting. The data are
presented as the percent phosphatase activity relative to
untransfected and untreated He La cells. All data are presented
as the mean±SD. of3 replicate experiments.
FIGS. SA-SI. Cell death induced by 10 nM microcystin LR
(MC-LR) 6 hours after treatment. UntreatedOATP1B1 transfected HeLa cells (Panels A, Band C), 10 nM treated vector
control (piRESneo2) transfected HeLa cells (Panels D, E and
F), and 10 nM treated OATP 1B 1 transfected He La cells (Panels G, Hand I). Brightfield images used to visualize cellular
morphology (Panels A, D and G). Fluorescent images showing Hoechst 33258 stain to visualize nuclear morphology and
DNA condensation (Panels B, E and H), Flow cytometry plots
of Side scatter (SSC) versus Forward scatter (FSC) displaying
the changes in cell size and the formation of cell fragments
(Panels C, F and I).
FIG. 6. The structure ofmicrocystin LR. The positions of
the two variable amino acids leucine (L) and arginine (R) that
are specific for microcystin LR are shown.
FIG. 7. OATP1B1 RNA levels determined using quantitative reverse transcription polymerase chain reaction (RT
PCR) and normalized to the expression of~ -actin. OATP 1B 1
levels were analyzed in the in the stable in vitro HeLa cell

lines and tumor masses excised from untreated athymic nude
mice 5 and 13 days after implantation. HeLa/piRES is a
control cell line that contains an empty expression vector.
Expression levels in the OATP1B1 tumors are comparable
with the levels seen in the OATP1B1 cell line.
FIG. 8. OATP1B1-expressing cancer cells were injected
into the flanks of athymic nude mice. After palpable tumors
were formed, cohorts were either injected with saline 5 days
per week with saline (controls, 'saline QDx5', squares);
injected with microcystin LR 25 flg/kg 5 days per week
(MCLR QDx5, triangles); or injected withmicrocystin LR 35
flg/kg every other day (MCLR QOD, diamonds). Tumors
were measured every two days. The results represent the
average±SD of cohorts of 3 or 4 mice.

5

10

15

DETAILED DESCRIPTION OF THE INVENTION

20

25

30

35

40

45

50

55

60

65

Our interest in microcystins as potential therapeutic molecules began with our finding that OATP1B3 mRNA is upregulated in non-small cell lung cancer (NSCLC). Therefore,
the anticancer potential of microcystin compounds might be
exploited by targeting these compounds to tumors that are
known to express OATP1B1 and OATP1B3.
Given that the microcystins are potent protein phosphatase
inhibitors, they are likely to affect both cell cycling and apoptosis. PP1 and PP2A directly regulate the activity of proteins
phosphorylated on serine or threonine residues. PP2A has
been shown to regulate the activity of at least 50 protein
kinases involved in critical aspects of the regulation of cell
division and cell death, including PKC, Akt, ERK, MEK, I KB
kinase, p38 and caspase-3 (8-10). Inhibition of PP2A (by
okadaic acid) has been shown to increase the phosphorylation
and subsequent activation of p53 leading to cell cycle arrest
and apoptosis (11, 12). Recent studies have identified PP2A
as a key regulator ofBCL-2 (13). Pharmacological inhibition
or RNAi knockdown of PP2A caused proteasomic degradation ofphosphoryated BCL-2 and sensitized the cells to various cell death stimuli. Therefore, we hypothesized that tumor
cells might be selectively sensitive to microcystin-induced
phosphatase inhibition. To test this hypothesis we transfected
cancer cells with the drug transporters OATP1B1 and
OATP1B3 to create in vitro models in which microcystins
could gain intracellular access, and the potential cytotoxicity
of microcystins in cancer cells could be assessed.
As used herein, the term "cancer" is meant to include
tumors, such as primary tumors that are the original neoplasm. The term "cancer" is also meant to include metastatic
disease, metastases, and metastatic lesions, which are groups
of cells that have migrated to a site distant relative to the
primary tumor.
The term "cancer" embraces a collection of malignancies
with each cancer of each organ consisting of numerous subsets. Typically, at the time of cancer diagnosis, the "cancer"
consists in fact of multiple subpopulations of cells with
diverse genetic, biochemical, immunologic, and biologic
characteristics.
Preferably, the cancer is malignant.
The types of cancers to be treated by the methods of the
instant invention are those that exhibit at least one of the
organic anion transporters OATP1B1 and OATP1B3. Preferably, the cancers exhibit OATP1B3.
Preferred cancers include but are not limited to hepatocellular cancer, gastrointestinal cancer, lung cancer, gastric cancer, colon cancer, pancreatic cancer, gall bladder cancer,
breast cancer, glioblastoma, and metastatic cancers and intraperitoneal disseminations thereof. The hepatocellular cancer
can be hepatocellular carcinoma. The gastric cancer can be
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signet ring cell cancer of the stomach, signet ring carcinoma,
or rubular adenocarcinoma. More preferred cancers are hepatocellular cancer, gastrointestinal cancer, and non-small cell
lung cancer.
The microcystin can be a substrate of and thus target one or
both of the organic anionic transporters OATP1B1 and
OATP1B3. Preferably, the microcystin is a substrate of
OATP1B3.
The microcystins contemplated for use in treating the
above cancers may include compounds with the basic structure cyclo (D-Ala-X-erythro-~-methyl-D-iso-Asp-Y-Adda
D-iso-Glu-N-methyldehydro-Ala), where X andY represent
variable amino acids, andAdda is the ~-amino acid, 3-amino9-methoxy-2,6,8-trimethyl-1 0-phenyldeca-4,6-dienoic acid.
Preferably, X andY are L amino acids.
The microcystins can be naturally-occurring. At least fifty
naturally-occurring microcystin analogs are known (WHO,
Geneva: World Health Organization 1998:95-110). A preferred naturally-occurring microcystin is microcystin LR
(FIG. 5), in which X is leucine andY is arginine. Naturallyoccurring microcystins can be isolated from natural sources,
or can be synthetic structural equivalents of microcystins that
can be isolated from natural sources.
The present invention also contemplates the use of novel
synthetic microcystins for treatment of cancer. Novel synthetic microcystin analogs having beneficial biological
effects can be designed using combinatorial engineering. A
person of ordinary skill in the art will recognize that there are
various methods applicable to microcystin synthesis, including solid phase peptide synthesis. Examples are described in
the literature, including Aggen et a!., Bioorg Med Chern
1999; 7:543-564; Gulledge et a!., Bioorg Med Chern Lett
2003; 13:2903-2906; and Gulledge eta!., Bioorg Med Chern
Lett 2003; 13:2907-2911.
The present invention also contemplates the use of microcystins with improved cytotoxicity, i.e., microcystins having
at least one of an improved cytotoxic potency or improved
cytotoxic selectivity as compared to microcystin LR.
Microcystins with improved cytotoxic potency, or greater
cytoxic potency than microcystin LR, demonstrate IC50 values lower than the IC 50 values of microcystin LR in cells
transfectedwithOATP1B1 andlorOATP1B3, with no significant increase in toxicity in control cells. Preferably, microcystins with improved cytotoxic potency demonstrate IC 50
values lower than the IC 50 values of microcystin LR in cells
transfected with OATP1B3. Examples of microcystins with
improved cytotoxic potency are microcystin LF and microcystin LW, as shown in the present Examples.
Microcystins with improved cytotoxic selectivity as compared to the selectivity of microcystin LR demonstrate an
improved differential toxicity between cells transfected with
OATP1B1 as compared to OATP1B3. Because the present
invention contemplates treatment of cancers expressing
OATP1B3 and not OATP1B1, cancers expressing OATP1B1
and not OATP1B3, and cancers expressing both transporters,
a person of ordinary skill in the art will readily recognize that
the definition of an "improved" differential toxicity will vary
with the particular cancer to be treated. Preferably, microcystins with improved cytotoxic selectivity demonstrate an
increased relative cytotoxicity in cells transfected with
OATP1B3 as compared to cells transfected with OATlBl.
Examples of microcystins with increased relative cytotoxicity in cells transfected with OATP1B3 as compared to cells
transfected with OAT1B1 are microcystin LF, microcystin
LW, microcystin RR, and microcystin YR, as shown in the
present Examples.

The present invention also contemplates microcystins with
improved cytotoxicity with regard to the organic anion transporter OATP1A2, which is also known to mediate the cellular
uptake of microcystins. For example, if the cancer exhibits
OATP1B3, it may be beneficial to treat a patient with an
improved microcystin analog that is a substrate for
OATP1 B3, but has reduced affinity (including no affinity) for
OATP1A2 and/or OATP1Bl.
Particularly referred microcystins with improved cytotoxicity are microcystin LF, in which X is leucine and Y is
phenylalanine, and microcystin LW, in which X is leucine and
Y is tryptophan.
The microcystins can be used alone, in combination with
each other, or in combination with other cancer modalities,
such as but not limited to chemotherapy, surgery, radiotherapy, hyperthermia, immunotherapy, hormone therapy,
biologic therapy (e.g., immune effector mechanisms resulting
in cell destruction, cytokines, immunotherapy, interferons,
interleukin-2, cancer vaccine therapy, and adoptive therapy),
and drugs to ameliorate the adverse side effects of such cancer
modalities.
As described herein, microcystins form a family of structurally related cyclic peptides. An individual member of the
microcystin family can be referred to variously herein as a
"microcystin," a "microcystin analog,'' a "microcystin variant," or a "microcystin compound."
The terms "treating", "treatment", and the like are used
herein to generally mean obtaining a desired pharmacological
and physiological effect. More specifically, the reagents
described herein which are used to treat a subject with cancer
generally are provided in a therapeutically effective amount
to achieve any one or more of the following: inhibited tumor
growth, reduction in tumor mass, loss of metastatic lesions,
inhibited development of new metastatic lesions after treatment has started, or reduction in tumor such that there is no
detectable disease (as assessed by, e.g., radiologic imaging,
biological fluid analysis, cytogenetics, fluorescence in situ
hybridization, immunocytochemistry, colony assays, multiparameter flow cytometry, or polymerase chain reaction). The
term "treatment", as used herein, covers any treatment of a
disease in a mammal, particularly a human.
The term "subject" or "patient" as used herein is meant to
include a mmal. Preferably the mammal is human.
The term "pharmaceutically effective" as used herein
refers to the effectiveness of a particular treatment regime.
Pharmaceutical efficacy can be measured based on such characteristics (but not limited to these) as inhibition of tumor
growth, reduction of tumor mass, reduction of metastatic
lesions as assessed, for example, by radiologic imaging,
slowed tumor growth, lack of detectable tumor associated
antigens, and the like. Additional methods of assessing tumor
progression would be known to the treating and diagnosing
physicians.
By "pharmaceutically effective amount" is meant an
amount of an agent, reagent, compound, composition, or
combination of reagents disclosed herein that when administered to a mammal is sufficient to be effective against the
cancer.
The present invention contemplates the use of microcystins
in combination with other cancer modalities or treatments.
Many treatments exist for cancers. The particular cancer
therapy or combination of therapy modalities used to treat a
cancer depend greatly on the type of cancer, its stage, the
patient (e.g., weight, sex, age, health, prior cancers, and the
like), and where the patient is in therapy (e.g., first treatment,
in blast crisis, refractive to initial treatments, cancer relapse,
or a second cancer perhaps induced by the treatment of the
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first cancer months or years before). Therefore, physicians
will frequently have to combine a variety of treatment modalities that will best suit the needs of the patient in combating the
disease and the patient's self-determination of quality oflife.
Treatment modalities include but are not limited to surgery,
radiation therapy, chemotherapy, biologic therapy (e.g.,
cytokines, immunotherapy, and interferons), hormone therapies, and hyperthermia.
Conventional chemotherapy can be further broken down
into hormone therapies (e.g., anti estrogens, aromatase inhibitors, gonadotropin-releasing hormone analogues, and antiandrogens), anti-tumor alkylating agents (e.g., mustards,
nitrosoureas, tetrazines, and aziridines ), cisplatin and its analogues, anti-metabolites (e.g., methotrexate, antifolates,
5-fluoropyrimidines, cytarabine, azacitidine, gemcitabine,
6-thipurines, and hydroxyurea), topoisomerase interactive
agents, antimicrotubule agents (e.g., vinca alkaloids, taxanes,
and estramustine ), differentiating agents (e.g., retinoids, vitamin D3, polar-apolar compounds, butyrate and phenylactetate, cytotoxic drugs, cytokines, and combinations thereof),
and other chemotherapeutic agents such as fludarabine,
2-chlorodeoxyadenosine, 2'-deoxycoformycin, homoharringtonine (HHT), suramin, bleomycin, and L-asparaginase.
Furthermore, the present invention contemplates delivery
of the microcystins in combination with drugs (such as
N -acetyl cysteine) that may selectively detoxifY microcystins
in hepatocytes but not in cancer cells, in order to decrease the
hepatotoxicity of microcystin treatment.
The microcystins of interest discussed above preferably are
administered as pharmaceutical compositions comprising
pharmaceutically acceptable carriers, diluents, and/or excipients, which are vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The carriers, diluents and/or excipients are not intended
to have biological activity themselves, and are selected so as
not to affect the biological activity of the microcystins and
any other active agent(s ). A pharmaceutically acceptable carrier, diluent, and/or excipient as used herein includes both one
and more than one such carrier, diluent, and/or excipient.
Examples include but are not limited to distilled water, physiological phosphate-buffered saline, Ringer's solutions, dextrose solution, and Hank's solution.
Depending upon the manner of introduction, the microcystins may be formulated as, for example, sterile injectable
formulations comprising aqueous solutions and/or suspensions containing the active materials in admixture with suitable carriers, diluents, and/or excipients. Formulations for
oral use may be in the form of tablets or capsules.
The concentration of therapeutically active microcystins in
the formulation (i.e., a formulation that is therapeutically
effective to the subject to which it was administered) and the
dose administered can be readily determined by a person of
ordinary skill in the art. Typically, dosages used in vitro and in
animal models may provide useful guidance in the amounts
useful for in vivo administration. Preferably, the dose administered will be less than the hepatotoxic dose.
The microcystins may be administered locally or systemically in a therapeutically effective dose.
The methods of administration include but are not limited
to parenteral administration, including subcutaneous (s.c.),
subdural, intravenous (i.v.), intramuscular (i.m.), intrathecal,
intraperitoneal (i.p.), intracerebral, intraarterial, intralesional, and pulmonary (e.g., via aerosols, inhalation, or powder) routes of administration. Administration can be via surgical application or surgical suppository. Oral administration
is also contemplated.

According to one aspect of the invention, a microcystin
may be administered alone, or in combination with other
agents as discussed above to treat and/or ameliorate a cancer.
Administration of other cancer therapeutic agents can occur
prior to, concurrent with, or after administration with the
microcystins. Administration of the microcystins can occur
before, during or after surgical treatment, radiotherapy, hormone therapy, immunotherapy, hyperthermia, or other cancer
treatment modality. Administration of the microcystins can
occur daily, weekly, or monthly as needed.
One aspect of the invention contemplates a method of
screening for microcystins with improved cytotoxicity.
Microcystins with improved toxicity are described above.
The present invention contemplates using cells transfected
with at least one ofOATlBl and OAT1B3 to determine the
cytotoxicity of candidate microcystin analogs. In one aspect
of the invention, transfected cells are treated with the microcystin, followed by determination of cell growth. In another
aspect of the invention, phosphatase inhibition in the microcystin-treated cells is measured.
It must be noted that as used herein, the singular forms "a",
"and", and "the" include plural referents unless the context
clearly dictates otherwise. Thus, for example, reference to "a
microcystin" or "microcystin analog" includes a plurality of
such microcystins or microcystin analogs, and reference to
"the dosage" includes reference to one or more dosages and
equivalents thereof known to those skilled in the art, and so
forth.

10

15

20

25

30

EXAMPLES
Abbreviations

35

40

45

50

55

60

65

OATP, Organic Anion Transporting Polypeptide; PPl, protein phosphatase-!; PP2A, protein phosphatase-2A; LST,
Liver Specific Transporters; NSCLC, non-small cell lung
cancer; PKC, Protein Kinase C; Akt, Protein Kinase B, ERK,
extracellular signal-regulated kinases, MEK, MAPK kinase,
IKB kinase, Inhibitor of KB kinase; DMEM, Dulbecco's
Modified Eagles Medium; FBS, fetal bovine serum; DOC,
Sodium deoxycholate; TBS, Tris buffered saline; CCK-8,
Cholecystokinin Octapeptide; BSP, Bromosulfophthalein;
SRB Sulforhodamine B; TCA, Trichloracetic Acid; DTT,
dithiothreitol; MyBP, Myelin Basic Protein; JNK, c-Jnn
N-terminal kinase; NAC, N-acetylcysteine; BSO, buthionine
sulfoximine; SSC, Side scatter: FSC, Forward scatter.
Materials and Methods
Reagents and Cell Culture.
HeLa cervical adenocarcinoma cells were obtained from
the American Type Culture Collection (Manassas, Va.). Dulbecco's Modified Eagles Medium (DMEM) containing
GLUTAMAX™-I, fetal bovine serum (FBS), phosphate
buffered saline (PBS) pH 7.2 and LIPOFECTAMINE™ 2000
were purchased from Gibco (Carlsbad, Calif.). Lung tumor
specimens and matched adjacent non-malignant tissue pairs
were obtained from the NCI Cooperative Human Tissue Network (CHTN; Columbus, Ohio). Normal liver eDNA was
purchased from Biochain Institute, Inc (Hayward, Calif.).
Microcystins LR and YR were purchased from Sigma, (St
Louis, Mo.). Microcystin LF, LW, RR and Okadaic acid were
all purchased from Axxora, LLC (San Diego, Calif.).
33
[
P]-ATP was purchased from PerkinElmer (Boston, Mass.).
All other chemicals were purchased from Sigma.
Transporter Gene Expression Analysis by Quantitative
PCR.
A protocol to screen anonymous lnng tumor specimens for
transporter gene expression was approved by the University
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of Kentucky Institutional Review Board. For each transporter
gene, we identified a primer set using the program Oligo 4.0.
In each case we demonstrated that the primers amplifY a PCR
product of expected length. Total RNA was extracted from
normal lung tissue and paired lung cancer specimens and cell
lines using the RNEASY kit (QIAGEN) with an on-column
DNase digestion. A total of 3 flg of RNA was used as a
template for the first-strand eDNA synthesis using the THERMOSCRIPT™ RT-PCR system (Invitrogen, Carlsbad, Calif.)
with Oligo(dT) as the primer and performed according to the
manufacture's protocol. Quantitative real-time PCR was performed using the SYBR® Green PCR Kit (Applied Biosystems; Foster City, Calif.) and the iCyclerthermal cycler (BioRad). Quantification was performed using iCycler analysis
software. The fluorescence threshold was set above the baseline in the exponential phase of the PCR and from this the Ct
(threshold cycle) was calculated for each reaction. The number of cycles required to reach the threshold fluorescence is
proportional to the amount target RNA in the sample. The
relative expression levels of the target genes were determined
by calculating the relative amounts of RNA from PCR standard curves (eDNA from liver, kidney or placenta was used as
standards for the lung tissue expression analysis, plasmid
DNA was used to for the cell line expression analysis), followed by normalization to the endogenous reference gene
~-actin. All PCR products of the samples displayed a single,
sharply melting curve with a narrow peak. Both OATP1B1
and OATP1B3 share >80% homology at the nucleotide level,
therefore primer specificity was confirmed by the inclusion of
a negative control to each analysis, (plasmid containing the
alternative gene). Neither of the primer sets amplified the
other gene.
Transient Expression ofOATP1B1 and OATP1B3.
OATP1B1 andOATP1B3 cDNAsinsertedintothemultiple
cloning site ofthevectorpiRESneo2 were obtained from Drs.
Meier and Hagenbuch at the University of Zurich, and the
nucleotide sequences of the coding regions were confirmed
by nucleic acid sequencing.
Exponentially growing HeLa cells were seeded at 2x10 5
cells/well in 6-well plates in 2 ml of DMEM supplemented
with 5% fetal calf serum (without antibiotics). The cells were
transfected 24 hours later using LIPOFECTAMINE™ 2000
(Invitrogen) at a ratio oflipid:DNAof2:1 (2 f.tl: 1 flg). In short,
2 fll of LIPOFECTAMINE™ 2000 diluted into 200 fll of
OPTI-MEM® (Invitrogen), at the same time 1 flg of plasmid
DNA is also diluted into 200 fll ofOPTI-MEM® and left to
equilibrate for 5 minutes. The DNA and LIPOFECTAMINE™ 2000 dilutions were mixed by pipetting and
complexes allowed to form for 25 minutes. During complex
formation the cells were washed cells once with 37° C. PBS
and 600 fll ofDMEM supplemented with 5% fetal calf serum
was added to each well. After 25 minutes, the complex mixture (400 fll) was carefully added to the cells, mixed gently,
and the transfection allowed to proceed at 37° C., in 5% C0 2
for 4 hours. After 4 hours 1 ml ofDMEM supplemented with
10% fetal calf serum was added to each well and the cells
returned to the incubator.
Western Blot Analysis.
Cells were washed twice in ice-cold PBS, lysed without
trypsinisation for 10 minutes at 4 o C. using a lysis buffer
containing 150 mMNaCl, 50 mMTris.Cl, pH 8.0, 1% NP-40,
0.5% DOC, 0.1% SDS and 0.02% sodium azide and 80 fll/ml
of Complete Protease Inhibitor cocktail (Roche Applied Science, Indianapolis, Ind.). Samples were passed through a
25-gauge needle 10 times, and the lysate collected following
centrifugation at 12,000 g for 5 minutes at 4° C. Protein
concentrations were determined using the Bio-Rad DC pro-

tein assay (Bio-Rad, Hercules, Calif.). Equal amount of protein (25 f.tg/lane) were separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE) and subsequently
transferred to PROTRAN BA85 nitrocellulose membrane
(Whatman, Inc. Sanford Me.). The membranes were incubated with antibodies against PP1 and PP2A (Santa Cruz
Biotechnology, Inc. Calif.) in 5% non-fat milk. After washing
with TBS-Tween the membranes were incubated with peroxidase-conjugated goat anti-mouse or goat anti-rabbit antibody
(Jackson Immunoresearch Laboratories, Inc., West Grove,
Pa.) in 5% non-fat milk, followed by visualisation using the
enhanced chemiluminescence system (Amersham Biosciences, Piscataway, N.J.). ~-actin (Sigma) was used to confirm equal protein loading.
Drug Uptake Studies.
Exponentially growing HeLa cells were transiently transfected with the plasmids containing OATP1B1, OATP1B3 or
empty piRESneo2 as described above. 48 hours after transfection, the cells were exposed to two commercially available, radio labeled substrates in uptake buffer (142 mM NaCl,
5 mM KCl, 1 mM K 2 HPO4 , 1.2 mM MgSO4 , 1.5 mM CaC1 2 ,
Glucose5mMandHEPES 12.5mM-pH7.3): [3 H]-BQ123
(Amersham Biosciences, N.J.) for 30 minutes (final concentration 0.5 f.LM), a substrate for both transporters (14) and
3
[ H]-CCK-8 (Cholecystokinin Octapeptide, Amersham Biosciences) for 10 minutes (5 nM), a substrate specific for the
OATP1B3 transporter (14). The uptake assay was terminated
by aspiration of the medium and three successive washes with
ice-cold PBS. The cells were air dried and solubilized by
overnight incubation in 0.2 N NaOH, followed by neutralization with 0.2 N HCI. The amount of intracellular radioactivity
in the lysates was determined by liquid scintillation counting.
The results were calculated by the subtraction of time-zero
counts followed by normalization to the amount of cellular
protein present in the lysates, which was determined spectraphotometrically using the Bio-Rad protein assay. Inhibition
of transport was performed by coincubation with 50 f.LM
bromosulfophthalein (Sigma).
Growth Inhibition Studies.
Cells were taken 24 hours following transfection and
seeded into 96 well plates at 1x104 cells/ml (1 x1 0 3 cells/well)
and allowed to adhere for a further 24 hours prior to drug
treatments. The cells were then exposed to serial dilutions of
the microcystin analogs prepared in culture medium for 72 hr.
Experiments in which cells were exposed to microcystin LR
for 1 and 6 hours, the media was carefully aspirated from the
wells and replaced with 200 fll of fresh media. Cellular
growth was determined using the sulforhodamine B (SRB)
protein dye assay (15). In short, cells were fixed with 50%
TCA w/v (50 fll/well) for 1 hour at 4 o C. Following fixation,
the plates were washed 5-6 times in water and stained with
SRB (0.4% SRB (w/v) in 1% (v/v) acetic acid) for30minutes
at 37° C. Excess stain was removed by washing 5 times in 1%
(v/v) acetic acid. The plates were subsequently air-dried and
the protein-bound SRB re-solubilized by the addition of 10
mM Trizma Base, pH 10.5. Colorimetric readings were made
at 570 nm. The IC 50 was calculated from the dose response
curve as the concentration of drug that produced a 50%
decrease in the mean absorbance compared to the untreated
wells.
Clonogenic Survival Studies.
HeLa cells were transiently transfected with OATP1B1,
OATP1 B3 or empty piRESneo2 as described above. 48 hours
after transfection, cells were seeded into 60 mm culture
dishes at 200 cells/dish in 5 ml of media. 6 hours after seeding, microcystin LR was added to duplicate dishes and left for
a further 72 hours. Following microcystin LR exposure, the
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media was careful aspirated from the dishes and replaced with
5 ml offresh media. The dishes were left for approximately 7
days until colonies were visible, at which time the cells were
washed once with PBS, fixed using Camoy's Fixative
(methanol:acetic acid-3: 1) for 5 minutes and stained using
0.4% crystal violet dissolved in water. The number of colonies on each plate was counted by eye and survival calculated
as the percentage of control. The LC 50 was extrapolated from
the graph and is defined as the concentration at which the
number of colonies was 50% of the control. The cloning
efficiency is each transfected cell line was >95%.
Inhibition of Purified Protein Phosphatases.
Phosphatase activity was determined using the Protein
Serine/Threonine Phosphatase (PSP) Assay System (New
England BioLabs Inc. MA). The in vitro activity of purified
PP1 (New England Biolabs) and PP2A (Upstate Cell Signaling Solutions, NY) was assayed according to the manufacturers instructions. Briefly, PP1 or PP2A were diluted in
phosphatase assay buffer (50 mM Tris-HCl (pH 7.5), 0.1 mM
Na 2 EDTA, 5 mM DTT and 0.01% Brij 35) at a concentration
were the enzyme concentration is linear with dephosphorylation (""30%) of the [33 P]-ATP labeled Myelin Basic Protein
(MyBP). The inhibitory effects of okadaic acid and the microcystin analogs, was determined by pre-incubation of the
enzymes with serial dilutions of each compound for 10 minutes prior to the addition of the radio labeled substrate. [33 P]MyBP was added to the reaction (final reaction volume 50 fll)
and immediately incubated at 30° C. for 10 minutes. The
reaction was stopped by the addition of 200 fll of ice-cold
20% TCA and incubated for a further 10 minutes on ice. The
precipitated protein was pelleted by centrifugation at 12,000
g at 4 o C. for 5 minutes, following which 200 fll of the
supernatant was carefully removed and the amount of
released 33 P determined by liquid scintillation counting. The
data were normalized to a duplicate control reaction performed in the absence of the phosphatases. The IC 50 was
calculated as the concentration of drug that inhibited the
release of 33 P compared to an uninhibited control reaction.
Intracellular Protein Phosphatase Analysis.
To determine the effects of the microcystins on the activity
of the intracellular phosphatases in the transiently transfected
HeLa cells, celllysates were prepared as follows. 48 hours
following transfection, HeLa cells transfected with either
piRESneo2, OATP1B1 or OATP1B3 were treated with
microcystin analogs and okadaic acid at approximately IC 90
concentrations for 6 hours. The cells were subsequently
washed in ice-cold PBS and 500 fll of the phosphatase assay
buffer containing 80 fll/ml of Complete Protease Inhibitor
cocktail was added to each well, the cells were immediately
scraped, collected in 1.5 ml microcentrifuge tubes and freeze/
thawed twice in dry-ice/room temperature water. The cells
were further lysed by repeated pipetting (x10) and immediately centrifuged at 12,000 g for 10 minutes at 4° C. The
remaining supernatant was collected and frozen at -80° C.
The protein concentration of the cell lysates was measured
using the Bio-Rad protein assay. To determine the levels of
phosphatase inhibition in the microcystin treated cells, 20 ng
of cellular protein was incubated in phosphatase assay buffer
in the presence of [33 P]-ATP labeled MyBP as described
above. The results are presented as the percent of total phosphatase activity relative to untransfected untreated HeLa
cells.
Cellular and Nuclear Morphology Studies.
HeLa cells were transiently transfected with OATP1B1 or
empty piRESneo2 as described above. Forty eight hours after
transfection, the cells were treated with 10 nM microcystin
LR for 6 hours. Floating and adherent cells were subsequently

pooled and washed once with ice cold PBS. Cells were then
either fixed in Carnoy's fixative or live cells immediately
analyzed by flow cytometry, (SSC-side scatter (granularity)
versus FSC-forward scatter (relative size), to determined
changes in gross cell morphology relative to a control (untreated) population. Flow cytometry was performed using a
BD FACSCALIBUR™ system (BD Biosciences, NJ). Fixed
cells were stained with Hoechst 33258 (1 flg/ml dissolved in
PBS) and changes in nuclear/DNA morphology were determined by fluorescent con-focal microscopy. Brightfield and
fluorescent images were taken under a 40x oil immersion
objective using a confocal Leica DM IRBE inverted microscope equipped with a Spectra-Physics 2 photon sapphire/
titanium laser and transmitted light detector for differential
interference contrast and phase microscopy.
Results
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OATP1B3 Expression is Increased in NSCLC
Tumors Relative to Adjacent Non-Malignant Tissue
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We analyzed the expression of 19 drug and vitamin transport genes in 19 pairs of NSCLC tumors and surrounding
non-malignant tissue obtained from the NCI Cooperative
Human Tissue Network. RNA extracted from tumors was
analyzed for transporter gene expression using quantitative,
real-time PCR and the results were normalized to the expression of ~-actin. The ratio between the expression in tumor
compared to adjacent non-malignant tissue for each paired
sample was calculated and the median value for the series of
tumor-tissue pairs for each gene is presented in Table 1.
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Transporter

Gene symbol

OAT!
OAT2
OAT3
OAT4
OATP1A2
OATP1B3
OATP1C1
OATP2A1
OATP2B1
OATP3A1
OATP4A1
OCT!
OCT2
OCT3
OCTN1
OCTN2
RFC1
THTR1
THTR2

SLC22A6
SLC22A7
SLC22A8
SLC22All
SLC21A3
SLC21A8
SLC21A14
SLC21A2
SLC21A9
SLC21All
SLC21A12
SLC22A1
SLC22A2
SLC22A3
SLC22A4
SLC22A5
SLC19A1
SLC19A2
SLC19A3

Tumor/Normal Ratio
0.62
0.90
1.17
1.11
1.28
6.38
0.68
0.18
0.47
0.95
1.24
0.81
0.36
0.33
0.25
0.81
0.78
0.67
0.35

Table 1 shows relative expression levels of 19 drug and
vitamin transport genes in 19 pairs ofNSCLC tumors compared to surrounding non-malignant tissue, obtained from the
NCI Cooperative Human Tissue Network. DNase treated
mRNA was isolated from tissues as described in the Materials
and Methods. Following eDNA synthesis, expression levels
of each gene were analyzed using quantitative real-time PCR.
~-actin levels were used to normalize the expression and data
are presented as the ratio of the median tumor expression
compared to the median of the paired normal tissue.
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The mRNA of only one gene, OATP1B3 was found to be
up-regulated, by a median value of 6.4-fold in lung tumors
compared to surrounding normal tissue; whereas all of the
other transport genes showed little increase in expression. A
number of genes did show a decrease in lung tumor expressian with the transporters OATP2A1, OCT2, OCT3, OCTN1
and THTR2 all showing >3-fold drop in expression. The
decrease RNA levels of THTR2 in this series is consistent
with our previous study of THTR2 RNA levels in NSCLC,
which used a different set ofNSCLC tumor/tissue pairs and a
different methodology (hybridization of labeled probes to a
eDNA array) (16), and which also found a decrease in THTR2
RNA levels in NSCLC tumors relative to adjacent non-malignant tissue.
To further illustrate the changes in expression between
tumor and normal lung tissue, representative scatter plots for
OATP1B1 (A), THTR2 (B) and OATP1A2 (C) are shown in
FIG. 1. The solid line represents the median value presented
in Table 1; the dotted line represents a reference sample
showing the expression in a normal tissue known to express
each gene. Of particular interest is the increased expression of
OATP1B3 in a number of the lung tumor samples (FIG. lA)
which is comparable to the expression level ofOATP1B3 in
normal liver,

cell lines SNU-449, SNU-182 andHepB3. The SV40 immortalized hepatic cell lines THLE-2 and THLE-3 are also
shown.
5

HeLa Expression Models Exhibit Functional Activity
and Confers Increased Sensitivity to Microcystin LR
and Other Natural Microcystin Analogs
10
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Example 2
HeLa Transient Transfection Model Demonstrates
Equivalent Levels of Transporter Expression to Liver
and PP1 and PP2A Expression Suitable for the Study
of Microcystins
To explore whether OATP1B3 expression could confer
sensitivity to its toxic substrates (e.g. microcystin), and thus
be exploited as potential target in lung cancer, hepatic cancer
and other malignancies, a transgenic model ofOATP1B3 and
the closed related gene OATP1B1 was needed. Because of
their relative ease of transfection and capacity to express
trans genes, we performed initial investigations in HeLa cells
as a proof-of-principle. Exponentially growing HeLa cells
were transiently transfected with the expression plasmids
containing the OATP1B1 and OATP1B3 eDNA inserts, or a
plasmid without a eDNA insert (vector control). To confirm
the expression level of the cloned cDNAs and to determine
the approximate level of expression in the transfected HeLa
cells relative to both control cells and normal liver eDNA, we
performed real-time-PCR as shown in FIG. 2 (panels A and
B). These studies demonstrate that the RNA levels in the
transient transfection system approximate the levels seen in
normal adult liver. Of significant interest, we observed that
the hepatic-derived cell lines have lost expression of these
transporters in comparison to normal liver, and lung cancer
cell lines also have either very low or undetectable levels of
RNA expression of these transporter genes.
Since microcystins are known substrates ofOATP1B1 and
OATP1B3 and are also acknowledged inhibitors ofPP1 and
PP2A, it was important to demonstrate that HeLa, lung and
hepatic cancer cells express PP1 and PP2A, Western blot
analysis was performed using antibodies directed against PP1
and PP2A (FIG. 2, panels C and D). This study demonstrates
that both phosphatases are present in HeLa cells, indicating
that HeLa cells would make an appropriate in vitro model
system. The studies also show that PP1 and PP2A are present
in cell lines created from tumors that are known to express
OATP1B1 andlorOATP1B3: the lung cancercelllinesA549,
NCI-H460 and NCI-H23; and the hepatocellular carcinoma
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To determine whether the RNA expression in transiently
transfected HeLa cells resulted in functional activity of the
transport genes, we studied the uptake of radiolabeled
BQ123, a substrate for both OATP1B1 and OATP1B3 and
CCK-8, a substrate specific for OATP1B3 only. As shown in
FIG. 3, gene-specific uptake of BQ123 can be seen in both
OATP1B1- and OATP1B3-transfected cells (panel A), and
OATP1B3-specific uptake of CCK-8 can be seen in
OATP1B3-transfected cells (panel B). In both cases, uptake
activity was inhibited by an excess of BSP (50 f.LM), a known
competitive inhibitor of these transporters. These studies
demonstrate that the functional activity of the cloned, transfected genes is consistent with the previously reported substrate profile of these transporters (14 ). To determine whether
the functional expression ofOATP1B1 and OATP1B3 result
in change sensitivity to microcystin LR, we exposed the transfected HeLa cells to microcystin LR in a 72 hour growth
inhibition assay. As can be seen in FIG. 3C, the IC50 for
microcystin LR in OATP1B1 cells was 5±1 nM and the IC 50
for OATP1B3 cells was 39±8 nM, while the toxicity in the
control cells was not reached at 10 f.LM. Similar results were
seen using the clongenic assay (FIG. 3D), which again identified the differential sensitivity for microcystin LR between
OATP1B1 (LC 50 =2nM) andOATP1B3 ((LC 50 =30nM), with
no toxicity seen in the vector alone (piRESneo2) cells. These
results demonstrate the potential selective toxicity that the
expression of these transporter genes confer on HeLa cells
after exposure to microcystin LR.
To determine whether microcystin toxicity can be specifically inhibited in OATP1B1 and OATP1B3-transfected cells,
we performed a growth inhibition study with microcystin LR
in the presence or absence ofBSP. As can also be seen in FIG.
3C, BSP significantly shifted the growth inhibition curve to
the right, increasing the IC 50 for both OATP1B1 and
OATP1B3-transfected cells from 5 nM and 39 nM, respectively, to approximately 5 f.LM, further confirming the role of
OATP1B1 and OATP1B3 uptake in microcystin LR toxicity.
To further understand the activity of microcystin LR, we
exposed OATP 1B 1-transfected HeLa cells to microcystin LR
for 1, 6 and 72 hours (FIG. 3E). A 1 hour exposure was found
to be less active, whilst the 6 hour exposure was similar to 72
hours, identical results were obtained with OATP1B3-transfected cells (data not shown). This result demonstrates that
toxic effects of microcystin LR are rapid, reaching a maximum effect after only 6 hours of incubation.
We subsequently examined four other microcystin analogs
using growth inhibition assays in the transfected He La cells to
determine whether there was evidence that different structural analogs had greater potency or selectivity than microcystin LR. We also used okadaic acid, the classical phosphatase inhibitor that was not thought to have selective uptake
requirements, as a positive control. As shown in Table 2, two
of the analogs examined, microcystin LF and microcystin
LW, showed greater cytotoxic potency than microcystin LR,
with both demonstrating IC 50 values in both of the genetransfected cell lines of less than 1 nM, with no evidence of
toxicity in the vector-only transfected cells at concentrations
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up to 1 f.LM. Microcystin RR exhibited much less potent
cytotoxicity, with an IC50 of 3.8±2.3 f.LM and 0.58±0.40 f.LM
for OATP1B1 and OATP1B3-transfected cells, respectively.
Still, the transporter gene expression increased cytotoxicity
of microcystin RR, with the vector-transfected cells not
showing any cytotoxicity at concentrations up to 10 f.LM. Both
microcystins LR and RR demonstrated differential toxicity
between the cells transfected with the either OAPT1B1 and
OATP1 B3. This data demonstrates that structural variation in
the microcystin analogs provides a degree of transporter
selectivity.

Further evidence for the importance of selective phosphatase inhibition in cytotoxicity is provided in FIG. 4, which
shows the correlation between the data in Table 2. FIGS. 4A
and 4B show the relationship between the growth inhibition
IC 50 for the microcystin analogs and the in vitro enzyme
inhibition IC 50 ofPP2A and PP1, respectively, where microcystin LR is represented by the open square (excluded from
the linear regression analysis). In FIG. 4A, the near linear
relationship between HeLa growth inhibition and PP2A
enzyme inhibition (r>0.99) of 4 microcystin analogs (filled
squares) suggests that the activity of these analogs in the

10

TABLE2
Microcystin analog growth inhibition and protein phosphatase enzyme

inhibition
Growth Inhibition
Microcystin
analog

LR
LF
LW
RR
YR
Okadaic
acid

p!RESneo2
IC 50 (nM)
>10,000
>1000
>1000
>10,000
>1000
7.8 ± 1.5

OATP!Bl
IC 50 (nM)
5
0.4
0.3
3,800
90
2.2

±51
± 0.1
± 0.1
± 2,300
± 20
± 0.6

Enzyme Inhibition
OATP1B3
IC 50 (nM)

PPl
IC 50 (nM)

39
0.9
0.5
580
45
3.0

1.4±0.3
2.2 ± 1.5
3.1 ± 0.3
6.9 ± 0.01
18.0 ± 6.0
90 ± 17

±8
± 0.9
± 0.4
± 400
± 30
± 1.2

In Table 2, growth inhibition was determined in plasmid
transfected HeLa cells. Cells were seeded into 96 wells plates
24 hours following transfection with control plasmid
(piRESneo2), OATP1B1 or OATP1B3 containing vectors
and 24 hours later exposed to a range of microcystin concentrations for a further 72 hours. Growth inhibition was determined using the SRB dye assay as described in the Materials
and Methods. The IC 50 data presented in the table represent
the concentration at which the absorbance is 50% of the
untreated control wells, the IC 50 was determined by nonlinear regression (variable slope) analysis using the GRAPHPAD PRISM® software. Phosphatase enzyme inhibition was
determined using purified PP1 and PP2A enzyme. Enzyme
was incubated with the microcystins at a range of concentrations for 10 minutes prior to the addition of[ 33 P]-ATP labeled
Myelin Basic Protein. The de-phosphorylation reaction was
allowed to proceed for 10 minutes, after which the reaction
was stopped with TCA and released [33 P] was determined by
liquid scintillation counting as described in the Material and
Methods. The IC 50 was determined by non-linear regression
(variable slope) analysis using the GRAPHPAD PRISM®
software and represents the concentration at which the release
of [33 P] was inhibited by 50% compared to the untreated
enzyme control reaction. All data are presented as the
mean±SD. of ;;:3 replicate experiments.
Example 4

PP2A
IC 50 (nM)
0.18
0.30
0.24
22.0
3.3
0.40

30

35

40

45

50

55

Microcystins Demonstrate Both Potent and
Differential Inhibition of Protein Phosphatases

± 0.01
± 0.01
± 0.02
± 7.0
± 0.14
±0.18

HeLa cells is related more to PP2A inhibition than PP1 (FIG.
4B). Similar results were found in the HeLa cells transfected
with OATP1B3 (data not shown). The relation between cytotoxicity and PP2A inhibition is further supported by the
observation that the IC 50 s of the analogs for growth inhibition
and PP2A enzyme inhibition are both in the same sub-nanomolar range. The results with okadaic acid (closed square)
further support this conclusion.
We measured global phosphatase inhibition in the transfected HeLa cells exposed to approximately equitoxic (IC 90 )
concentrations of microcystins to further examine the relationship between the cytotoxic effects and protein phosphatase inhibition. In these studies, OATP1B3-transfected
HeLa cells and empty vector control cells were exposed for 6
hours to the microcystins at approximately equitoxic concentrations, and phosphatase activity in the cellular cytosol was
then measured. As can be seen in FIG. 4C, total phosphatase
inhibition does not directly correspond to cytotoxicity. For
example, at a dose of approximately 2-fold greater than the
cytotoxic IC 50 in OATP1B3-transfected HeLa cells, microcystin LF and LW (1 nM) had no discernable effect on total
phosphatase activity. At a similar equitoxic dose, microcystin
LR (1 0 nM) decreased total phosphatase activity by approximately 30% in OATP1 B 1-transfected cells. However, microcystin RR (1 f.LM) decreased total phosphatase activity by
90%. These results suggest that specific phosphatase inhibition, not global inhibition, is related to cytotoxicity. These
results also suggest that at higher concentrations, microcystins may have inhibitory effects on other phosphatases.
Example 5

The in vitro analysis of microcystin inhibition on purified
PP1 and PP2A phosphatases is also shown in Table 2. The
values determined are consistent with previously reported Ki
values for microcystin LR and okadaic acid. The reported Ki
values for microcystin-LR against PP1 and PP2A are 0.06-6
nM and <0.01-2 nM, respectively (17). Okadaic acid has a
reported IC 50 of 60-500 nM for PP1 and 15-70 nM for PP2A
(18).

60

Cell Death Induced by Microcystin LR is Rapid

65

FIG. 5 displays the results of microcystin LR induced cell
death after a 6 hour exposure. Using confocal microscopy and
changes in cell morphology shown by flow cytometry we
have identified that exposure to Microcystin LR induced
rapid changes in cell and nuclear morphology. Initial mor-
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phologic changes are rapid detachment from the culture surface, which occurs within the first hour of exposure (data not
shown). By 6 hours microcystin LR-treated OATPlBl
expressing cells, display membrane blebbing (FIG. SG), and
massive cellular fragmentation can be detected using flow
cytometry (FIG. 51). Using Hoechst 33258 DNA stain, we
also identified extensive chromatin condensation and fragmentation (FIG. SH) following a 6 hour microcystin LR exposure. Control (piRESneo2) transfectants similarly treated
with 10 nM microcystin LR showed no changes in cellular
morphology (FIGS. SD and F) and nuclear condensation
(FIG. SE), comparable to the untreated OATPlBl-transfected control (FIGS. SA, B and C), further supporting the
evidence that microcystins require a transport mechanism for
cellular uptake and toxicity. Taken together, these data demonstrate that once microcystin LR gains entry into cells it acts
rapidly causing morphological changes which are indicative
of cell death.

cells indicates both that the expression of these genes can
impart selective sensitivity of cancer cells to cytotoxic substrates, and that phosphatase inhibition may be a valid target
for anticancer drug development. Furthermore, the lack of
activity ofmicrocystin LR in the control HeLa cells demonstrates that the stumbling block for developing microcystins
as anticancer agents may be that these phosphatase inhibitors
have difficulty gaining intracellular access in standard in vitro
cytotoxicity models. This potential difficulty is supported by
both our observations and those of others, that even hepaticderived cell lines do not reflect the level of transporter gene
expression observed in the tissue and tumors of origin. In the
case ofOATPlBl we found no detectable expression in any
of the HCC or immortalized hepatocyte cell lines. In the case
of OATP1B3, the level of mRNA expression in HCC and
hepatocyte cell lines was at the limit of detection, and orders
of magnitude lower than the expression levels seen in normal
adult liver. In particular, the widely used Hep3B cell line does
not express OATPlBl and the level ofOATP1B3 is orders of
magnitude lower than the levels measured in normal liver.
Also, another widely used model of hepatocellular carcinoma, the HepG2 cell line, also does not express either transporter (7). Similarly, the level of RNA expression in lung
cancer cell lines is also low, even though direct measurement
of RNA levels in lung tumor tissue showed increased expression relative to normal lung tissue, with the increased expression in the tumor samples being comparable to that of a
normal liver reference. In the case of both transporters, the
constitutive levels in all of the hepatic cell lines was at the
level of the untransfected HeLa cells, whereas the transfected
He La cells had mRNA levels similar to the levels measured in
normal liver. We have seen a similar down regulation in cell
lines versus tumors in the case of another membrane transporter, OCT6 (19). Supporting our observations, the loss of
microcystin sensitivity in freshly isolated trout and murine
hepatocytes was observed to coincide with the rapid loss of
OATP transporter gene expression when the hepatocytes are
maintained in cell culture (20). Thus, down-regulation of
membrane transport that occurs in adaptation to in vitro
growth conditions has the potential to limit the interpretation
of cell culture-based screening systems for polar cytotoxins
that depend on specific mechanisms of drug uptake.
Since transporter gene expression in tumors caunot be
extrapolated from cell lines, direct measurement of tumor
gene expression is required. However, studies quantifying
mRNA levels in tumors also have limitations in interpretation. It is important to acknowledge that, while the data demonstrate increased expression of OATP1B3 mRNA in lung
tumors, these data must be interpreted with caution, as the
mRNA levels do not necessarily reflect either protein expression or function. The actual sensitivity ofNSCLC tumors to
microcystin analogs, and of microcystin uptake in NSCLC
tumors relative to hepatocytes, are important questions to be
explored with xenograft models (see, e.g., Examples 6 and 7
herein).
The microcystin concentrations that produced cytotoxicity
in the transfected HeLa cells in our study, in the sub-nanolar
range for microcystin LF and microcystin LW, appear to be
significantly less than the doses required for hepatic toxicity.
In mice given a sub-lethal dose ofmicrocystin LR (35 flg/kg),
the peak plasma concentration achieved was 428 nM (21),
compared to the IC 50 s of 5 nM and 39 nM for microcystin LR
in OATPlBl and OATP1B3-transfected HeLa cells, respectively (Table 2). Also, microcystin rapidly accumulate in the
liver, with 70% of the total dose accumulating in the liver by
30 min after the injection (21). We have demonstrated that the
cytotoxic activity of microcystin LR is rapid, and although

Example 6
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Xenograft Model
Clones of HeLa cells that stably express both OATP1B3
and OATPlBl have been isolated, and a preliminary study a
preliminary study with stable OATPlBl-expressing HeLa
cells transplanted into athymic nude mice has been conducted. The OATPlBl gene was chosen for initial studies of
hepatocellular carcinoma, a malignancy where OATPlBl is
expressed. Our in vitro data indicates that both OATP 1B 1 and
OATP1B3 effectively mediate the uptake of microcystins,
and can be expected to have similar function in vivo. We have
also demonstrated that this cell line can grow in vivo and that
the gene expression is maintained when grown as tumor
xenografts (FIG. 7).
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Example 7
OATPlBl-Expressing HeLa Xenografts Treated
with Microcystin LR
In this in vivo experiment of microcystin LR treatment,
OATPlBl-expressing cancer cells were implanted subcutaneously in the flanks of 10 athymic nude mice and microcystin LR was administered in two schedules by intraperitoneal
(IP) injection after tumors were established (FIG. 8). A cohort
of3 mice were injected with 35 flg/kg IP every other day and
a second cohort of 3 mice received daily injections of 25
flg/kg Monday through Friday. A cohort of 4 mice served as
controls and were injected IP with saline. The doses and
schedules were all the first approximations, and other microcystin analogs are more potent in vitro. The graph shown in
FIG. 8 shows the result of this first experiment, and demonstrates the proof-of-principle that established OATPlBl-expressing tumors respond to microcystin treatment. The
therapy was tolerated; all mice survived the treatment regimens. The weight in the control group was 22.7±1.3 grams at
day 0 and 26.1±2.0 grams at day 18; in the microcystin LR
cohort treated daily the weight was 22.8±2.7 grams on day 0
and 19.0±1.2 grams on day 18; and in the cohort treated every
other day, the weights were 21.6±0.8 grams on day 0 and
22.3±2.4 grams on day 18. The average tumor volume of the
cohort treated every other day was 49% of control on day 18.
Discussion
The observation that microcystin LR and its analogs show
potent growth inhibitory and cytoxicity activity in OATPl B land OATP1B3-transfected cells in comparison to control
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maximal activity was not seen until 6 hours, a 1 hour exposure
demonstrated significant levels of activity (FIG. 3E).
Our data strongly suggest that microcystin cytotoxicity in
He La cells is related to specific PP2A inhibition. We found no
correlation between global phosphatase inhibition and cytotoxicity. The similar concentrations for PP2A enzyme inhibition and growth inhibition, and the linear correlation
between the growthiC 50 and the enzyme IC 50 formicrocystin
analogs, both suggest that specific PP2A inhibition is related
to the toxic effect.
The high concentration of microcystin in the liver achieved
with a sublethal dose (21) suggests that hepatocytes may
differ from cancer cells in the mechanism of microcystin
toxicity. First, hepatic lethality may be related to an intracellular target other than PP2A. One such target may be aldehyde
dehydrogenase 11, an enzyme involved in acetetaldehyde
detoxification and prevention of free radical formation, which
was recently identified as a microcystin target from a peptide
fragment that physically associated with microcystin LR
using phage display methodology (22). Another potential
microcystin target is the ~ subunit of ATP-synthase, which
was shown to be a microcystin-binding protein using an antimicrocystin antibody affinity purification colunm (23).
Second, reports of microcystin cytotoxicity in non malignant cells, in which a significantly higher dose is required for
toxicity, is seemingly related to formation of reactive oxygen
species (24) and resultant DNA damage (25). In lymphocytes
in vitro, the mechanism of microcystin toxicity was associated with free radical formation; in those studies cells were
exposed to micromolar concentrations of microcystin LR (26,
27), in comparison to the sub-nanomolar range in the transfected HeLa cells.
Third, phosphatase inhibition may have different effects in
tumor cells versus normal cells. Although protein phosphatases have tumor suppressor properties, phosphatases
have been also been reported to promote cell growth and
survival (9, 10). The cytotoxic effect of phosphatase inhibition may depend upon the reliance of a particular cell on the
activity of specific kinases, which are often abnormally regulated in cancer. For example, the phosphatase inhibitor okadaic acid has been shown to induce apoptosis in a variety of
cell lines, with increased sensitivity reported in cells carrying
mutated Ras (28). Okadaic acid also induced apoptosis in
malignant glioma cells, in studies which suggested an integral
role for ERK and JNK kinases in promoting cell death (29).
Rapid apoptosis has also been seen in primary hepatocytes
following microinjection with both microcystin LR and
nodularin, characterised by cytoplasmic shrinkage, chromatin condensation, membrane blebbing and procaspase 3
cleavage (30). Similarly, we have identified rapid cell death
(within 6 hours), although at a much lower concentration (1 0
nM) than those used by Fladmark and colleagues (nodularin>250 f.LM and microcystin LR>50 f.LM).
Finally, in addition to potential differences in microcystin
intracellular targets between hepatocytes and cancer cells,
there are also numerous metabolic differences between the
normal hepatocyte and the malignant cell, and these differences might be exploited to create a therapeutic window for
microcystin toxins. Microcystin and the related toxic cyclic
peptide nodularin appear to stimulate glutathione-dependent
detoxification pathways in hepatocytes. Exposure of rat hepatocytes to sub-lethal concentrations of microcystin LR results
in an acute increase in intracellular glutathione and an
increase in the formation of reactive oxygen species (31 ).
Significantly, addition ofN-acetylcysteine (NAC) to the cuiture medium, an agent that increases intracellular glutathione
concentrations, decreased sensitivity of cultured rat hepato-

cytes to microcystic cyanobacteria extracts. Conversely,
buthionine sulfoximine (BSO), an agent that decreases intracellular glutathione, increased the sensitivity of the cultured
hepatocytes to the cyanobacteria extract (32). These studies
suggest that glutathione may play a role in the in vivo hepatic
detoxification of microcystins at high concentrations. In our
HeLa cell model, neither NAC nor BSO affected microcystin
toxicity (data not shown).
In conclusion, therapeutic microcystin analogs may have
the potential to exploit both differences in the mechanisms of
toxicity and the availability of detoxification mechanisms in
tumors versus normal hepatic tissue. The restricted hepatic
expressionofOATP1B1 and OATP1B3 would help to prevent
toxicities to non-malignant tissues other than liver, and the
expression of these transporters in NSCLC and hepatocellular carcinoma suggests that these tumors could be targeted
with transporter-specific cytotoxins. Microcystins, as stable
cyclic peptides with two variable amino acid positions, are
attractive candidates for combinatorial synthesis, and the
variation in potency between the first 5 microcystin analogs
tested suggests that other analogs may be even more potent.
While the present invention has been described with reference to specific embodiments, this application is intended to
cover those various changes and substitutions that may be
made by those of ordinary skill in the art without departing
from the spirit and scope of the appended claims.
The publications discussed herein are provided solely for
their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that
the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication
dates, which may need to be independently confirmed.
All publications cited herein are hereby incorporated by
reference in their entirety.
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2. The method of claim 1, wherein said microcystins are
Toxicology 2006; 218:134-48.
45 substrates of at least one ofOATP1B1 and OATP1B3.
21. Robinson N A, Pace J G, Matson C F, Miura G A,
3. The method of claim 2, wherein said microcystins are
substrates of both OATP1B1 and OATP1B3.
Lawrence W B. Tissue distribution, excretion and hepatic
4. The method of claim 2, wherein said microcystins are
biotransformation of microcystin-LR in mice. J Pharmacal
Exp Ther 1991; 256:176-82.
substrates ofOATP1B3 and not OATP1Bl.
22. Chen T, Cui J, Liang Y, eta!. Identification of human liver 50
5. The method of claim 2, wherein said microcystins are
mitochondrial aldehyde dehydrogenase as a potential tarsubstrates ofOATP1B1 and not OATP1B3.
get for microcystin-LR. Toxicology 2006; 220:71-80.
6. The method of claim 1, wherein said microcystin has at
23. Mikhailov A, Harmala-Brasken AS, Hellman J, Merileast one of improved cytotoxic potency and improved cytoluoto J, Eriksson J E. Identification of ATP-synthase as a
toxic selectivity as compared to microcystin LR.
novel intracellular target for microcystin-LR. Chern Bioi 55
7. The method of claim 1, wherein said microcystin is
Interact 2003; 142:223-37.
naturally-occurring.
24. Ding W X, Nam Ong C. Role of oxidative stress and
8. The method of claim 1, wherein said microcystin is
mitochondrial changes in cyanobacteria-induced apoptosynthetic.
sis and hepatotoxicity. FEMS Microbial Lett 2003; 220:
9. The method of claim 1, wherein said cancer comprises
1-7.
60 cells that express both OATP1B1 and OATP1B3.
25. Ding W X, Sherr H M, Zhu H G, Lee B L, Ong C N.
10. The method of claim 1, wherein said cancer comprises
Genotoxicity of microcystic cyanobacteria extract of a
cells that express OATP1B3 and not OATP1Bl.
water source in China. Mutat Res 1999; 442:69-77.
11. The method of claim 1, wherein said cancer comprises
26. LaukoffA, Carmichael WW, GrasmanKA, YuanM. The
cells that express OATP1B1 and not OATP1B3.
12. The method of claim 1, wherein said microcystin is
uptake kinetics and immunotoxic effects of microcystin- 65
administered at a dose that does not result in hepatic cytotoxLR in human and chicken peripheral blood lymphocytes in
icity.
vitro. Toxicology 2004; 204:23-40.
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13. The method of claim 1, wherein said microcystin is
administered as a pharmaceutical composition comprising
one or more of a pharmaceutically acceptable diluent, carrier,
and excipient.
14. The method of claim 1, wherein said microcystin is
administered in combination with other cancer modalities.
15. The method of claim 14, wherein said other cancer
modalities are selected from the group consisting of: chemotherapy, surgery, radiotherapy, hyperthermia, immunotherapy, hormone therapy, biologic therapy, and drugs to arneliorate the adverse side effects of said cancer modalities.
16. The method of claim 1, wherein said cancer is nonsmall cell lung cancer, and said microcystin is selected from
the group consisting of: cyclo (D-Ala-Leu-erythro-~-methylD-iso-Asp-Phe-Adda-D-iso-Glu-N-methyldehydro-Ala)
and cyclo (D-Ala-Leu-erythro-~-methyl-D-iso-Asp-Try
Adda-D-iso-Glu-N -methy ldehydro-Ala).
17. The method of claim 1, wherein said cancer is hepatocellular carcinoma, and said microcystin is selected from the
group consisting of: cyclo (D-Ala-Leu-erythro-~-methyl-Diso-Asp-Phe-Adda-D-iso-Glu-N-methyldehydro-Ala) and
cyclo (D-Ala-Leu-erythro-~-methyl-D-iso-Asp- Try-AddaD-iso-Glu-N-methyldehydro-Ala).
18. The method of claim 1, wherein said cancer is colon
cancer.

* * * * *
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